Meeting
2022 ASCO Annual Meeting
Systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of patients with cancer treated with immune checkpoint inhibitors.
Authors
Gerard Zalcman
Department of Thoracic Oncology, CIC INSERM 1425, Université de Paris, Hôpital Bichat, Paris, France
Gerard Zalcman , Athéna Crespin , Julie Cervesi , Clément Le Bescop , Renaud Buffet , Jean de Gunzburg , Fabien Vitry , Pierre-Alain Bandinelli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Monotherapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2585)
DOI
10.1200/JCO.2022.40.16_suppl.2585
Abstract #
2585
Poster Bd #
240
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association of proton pump inhibitor use with survival outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
First Author: BaoQing Chen
Poster
2021 ASCO Annual Meeting
The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).
First Author: Matthew Scott Ernst
Poster
2021 ASCO Annual Meeting
Proton pump inhibitors and antibiotics impact on toxicities and clinical outcomes in cancer patients treated with immunotherapy.
First Author: Haniel alves Araujo
Poster
2020 ASCO Virtual Scientific Program
Impact of timing of antibiotic use on clinical outcomes in patients with urothelial cancer treated with immune checkpoint inhibitors (ICIs).
First Author: Chana Weinstock